Hormonal therapies in septic shock

Journal of Pediatric Infectious Diseases

Volumn 4, Issue 2, 2009, Pages 119-126

  Felmet, Kate ^a   Choong, Karen ^b   Kissoon, Niranjan ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b MCMASTER CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Corticosteroids; Hormone; Insulin; Sepsis; Vasopressin

Indexed keywords

ARGIPRESSIN; CORTICOSTEROID; CORTICOTROPIN; FLUDROCORTISONE; HYDROCORTISONE; INSULIN; NORADRENALIN; PLACEBO; TERLIPRESSIN; VASOPRESSIN;

ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICAL ILLNESS RELATED CORTICOSTEROID INSUFFICIENCY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART STRESS; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LOW DRUG DOSE; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TISSUE PERFUSION; TREATMENT RESPONSE; UPREGULATION;

EID: 63049099307     PISSN: 13057707     EISSN: None     Source Type: Journal    
DOI: 10.3233/JPI-2009-0153     Document Type: Review

References (49)

1. I. Vanhorebeek and G. Van den Berghe, The neuroendocrine response to critical illness is a dynamic process, Crit Care Clin 22 (2006), 1-15.
2. G. Van den Berghe, F. de Zegher and R. Bouillon, Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms, J Clin Endocrinol Metab 83 (1998), 1827-1834.
3. L. Langouche and G. Van den Berghe, The dynamic neuroendocrine response to critical illness, Endocrinol Metab Clin North Am 35 (2006), 777-791.
4. M. Oppert, R. Schindler, C. Husung et al., Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock, Crit Care Med 33 (2005), 2457-2464.
5. J.A. Russell, Vasopressin in vasodilatory and septic shock, Curr Opin Crit Care 13 (2007), 383-391.
6. P.E. Marik, S.M. Pastores, D. Annane et al., Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine, Crit Care Med 36 (2008), 1937-1949.
7. M.F. de Jong, A. Beishuizen and A. Groeneveld, Defining relative adrenal insufficiency in the critically ill, in: Yearbook in Intensive Care and Emergency Medicine, J.L. Vincent, ed., Springer: Berlin, 2006, pp. 539-552.
8. K. Menon and M. Lawson, Identification of adrenal insufficiency in pediatric critical illness, Pediatr Crit Care Med 8 (2007), 276-278.
9. D. Lipiner-Friedman, C.L. Sprung, P.F. Laterre et al., Adrenal function in sepsis: The retrospective Corticus cohort study, Crit Care Med 35 (2007), 1012-1018.
10. K. Tordjman, A. Jaffe, Y. Trostanetsky, Y. Greenman, R. Limor and N. Stern, Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: Sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test, Clin Endocrinol 52 (2000), 633-640.
11. J.T. Ho, H. Al-Musalhi, M.J. Chapman et al., Septic shock and sepsis: A comparison of total and free plasma cortisol levels, J Clin Endocrinol Metab 91 (2006), 105-114.
12. B.M. Arafah, Hypothalamic pituitary adrenal function during critical illness: Limitations of current assessment methods, J Clin Endocrinol Metab 91 (2006), 3725-3745.
13. D.Keh and C. Sprung, Use of coritcosteroid therapy in patients with sepsis and septic shock: An evidence-based review, Crit Care Med 32 (2004), S527-S533.
14. D. Annane, E. Bellissant, P.E. Bollaert, J. Briegel, D. Keh and Y. Kupfer, Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis, BMJ 329 (2004), 480.
15. L. Cronin, D.J. Cook, J. Carlet et al., Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature, Crit Care Med 23 (1995), 1430-1439.
16. P.C. Minneci, K.J. Deans, S.M. Banks, P.Q. Eichacker and C. Natanson, Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose, Ann Intern Med 141 (2004), 47-56.
17. D. Annane, V. Sebille, C. Charpentier et al., Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock, JAMA 288 (2002), 862-871.
18. J. Cohen, G. Ward, J. Prins, M. Jones and B. Venkatesh, Variability of cortisol assays can confound the diagnosis of adrenal insufficiency in the critically ill population, Intensive Care Med 32 (2006), 1901-1905.
19. C. Sprung, D. Annane, D. Keh et al., Hydrocortisone therapy for patients with septic shock, New Engl J Med 358 (2008), 111-124.
20. B.P. Markovitz, D.M. Goodman, R.S. Watson, D. Bertoch and J. Zimmerman, A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: What is the role of steroids? Pediatr Crit Care Med 6 (2005), 270-274.
21. M. Min, U T, M. Aye, T.N. Shwe and T. Swe, Hydrocortisone in the management of dengue shock syndrome, Southeast Asian J Trop Med Public Health 6 (1975), 573-579.
22. Sumarmo, The role of steroids in dengue shock syndrome, Southeast Asian J Trop Med Public Health 18 (1987), 383-389.
23. K. Masumoto, S. Kusuda, H. Aoyagi et al., Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity, Pediatr Res 63 (2008), 686-690.
24. R.P. Dellinger, M.M. Levy, J.M. Carlet et al., Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008, Crit Care Med 36 (2008), 296-327.
25. S.J. Van Cromphaut, I. Vanhorebeek and G. Van den Berghe, Glucose metabolism and insulin resistance in sepsis, Curr Pharm Des 14 (2008), 1887-1899.
26. K.A. Wintergerst, B. Buckingham, L. Gandrud, B.J. Wong, S. Kache and D.M. Wilson, Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit, Pediatrics 118 (2006), 173-179.
27. J.S. Krinsley, Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients, Mayo Clin Proc 78 (2003), 1471-1478.
28. V. Srinivasan, P.C. Spinella, H.R. Drott, C.L. Roth, M.A. Helfaer and V. Nadkarni, Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children, Pediatr Crit Care Med 5 (2004), 329-336.
29. I. Vanhorebeek, L. Langouche and G. Van den Berghe, Tight blood glucose control with insulin in the ICU: Facts and controversies, Chest 132 (2007), 268-278.
30. G. Van den Berghe, P. Wouters, F. Weekers et al., Intensive insulin therapy in critically ill patients, N Engl J Med 345 (2001), 1359-1367.
31. G. Van den Berghe, A. Wilmer, G. Hermans et al.,. ntensive insulin therapy in the medical ICU, N Engl J Med 354 (2006), 449-461.
32. F.M. Brunkhorst, C. Engel, F. Bloos et al., Intensive insulin therapy and pentastarch resuscitation in severe sepsis, N Engl J Med 358 (2008), 125-139.
33. P. Devos, J. Preiser and C. Melot, Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: Final results of the Glucontrol study, Intensive Care Med 33 (2007), S189.
34. R.S. Wiener, D.C. Wiener and R.J. Larson, Benefits and risks of tight glucose control in critically ill adults: A meta-analysis, JAMA 300 (2008), 933-944.
35. E. Hirshberg, G. Larsen and H. Van Duker, Alterations in glucose homeostasis in the pediatric intensive care unit: Hyperglycemia and glucose variability are associated with increased mortality and morbidity, Pediatr Crit Care Med 9 (2008), 361-366.
36. N.A. Ali, J.M. O'Brien, Jr., K. Dungan et al., Glucose variability and mortality in patients with sepsis, Crit Care Med 36 (2008), 2316-2321.
37. C. Crtichell, V. Savarese, A. Callahan, C. Aboud, S. Jabbour and P. Marik, Accuracy of bedside capillary blood glucose measurements in critically ill patients, Intensive Care Med 33 (2007), 2079-2084.
38. J.C. Preiser, Restoring normoglycaemia: Not so harmless, Crit Care 12 (2008), 116.
39. National Instutites of Health: Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR study).
40. D.W. Landry and J.A. Oliver, The pathogenesis of vasodilatory shock, N Engl J Med 345 (2001), 588-595.
41. C.L. Holmes, D.W. Landry and J.T. Granton, Science review: Vasopressin and the cardiovascular system part 1 - receptor physiology, Crit Care 7 (2003), 427-434.
42. C.L. Holmes, D.W. Landry and J.T. Granton, Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology, Crit Care 8 (2004), 15-23.
43. M.W.Dünser,W.R. Hasibeder, V.Wenzel et al., Endocrinologic response to vasopressin infusion in advanced vasodilatory shock, Crit Care Med 32 (2004), 1266-1271.
44. K. Choong and N. Kissoon, Vasopressin in pediatric shock and cardiac arrest, Pediatr Crit Care Med 9 (2008), 372-379.
45. N.G. Morgenthaler, J. Struck, S. Jochberger and M.W.Dünser, Copeptin: clinical use of a new biomarker, Trends Endocrinol Metab 19 (2008), 43-49.
46. J.A. Russell, K.R. Walley, J. Singer et al., Vasopressin versus norepinephrine infusion in patients with septic shock, New Engl J Med 358 (2008), 877-887.
47. S. Meyer, L. Gortner, W. McGuire, A. Baghai and S. Gottschling, Vasopressin in catecholamine-refractory shock in children, Anaesthesia 63 (2008), 228-234.
48. K. Choong, A. Joffe, K. Menon et al., Vasopressin in pediatric vasodilatory shock trial. ISRCTN-Controlled Trials Registry 11597444. 2008.
49. C. Ertmer, S. Rehberg and M. Westphal, Vasopressin analogues in the treatment of shock states: Potential pitfalls, Best Pract Res Clin Anaesthesiol 22 (2008), 393-406.